Medicated feed premix addition in swine production: carry agent selection and mixer homogeneity limits

Tylvalosin tartrate premix is not dumped directly into complete swine feed. The drug-rich fraction is first diluted through a carry agent selected to match the bulk density of the premix. A horizontal ribbon mixer with a working volume between 60% and 80% of gross capacity is preferred because the low-shear folding action limits macrolide dust formation. The first dilution is commonly prepared as a 1:10 or 1:20 blend with ground corn, wheat middlings, or lactose monohydrate. The second dilution is metered into the complete feed at a computed inclusion rate based on the target animal weight class. Batch homogeneity is verified by taking 10–12 samples after 10 min of mixing and again after 15 min. The assay relative standard deviation should remain below 5% for a production-scale batch. When the bulk density difference between the premix and the carrier exceeds 0.2 g/cm³, segregation occurs during bin transfer and auger conveyance. In such cases, transfer drop height is maintained below 1.2 m and free-fall spouting into bulk bins is replaced by a dense-phase vacuum conveyor. Final feed moisture is held below 14 g/100 g to limit hydrolytic opening of the macrolide ring.

Regulatory control for this segment is defined by EU Regulation (EC) No 183/2005 for feed hygiene and US FDA 21 CFR Part 225 for medicated feed manufacturing. Batch records must show the sequence of addition, flush material, carryover amount, and assay result for each lot. Carriers with high cation-exchange capacity, such as kaolin or bentonite, should be avoided because irreversible adsorption of the tertiary amine function reduces assay recovery. The preferred carry agent is low-moisture ground corn with a particle size passing a 0.5 mm screen. The finished Type B or Type C medicated feed is administered within the approved in-feed period. The target swine disease complex includes Lawsonia intracellularis and Mycoplasma hyopneumoniae, so the medicated feed is normally directed to nursery, grower, and finisher units. Feed intake variation between 0.5 kg/day and 1.1 kg/day in nursery pigs requires the inclusion rate to be calculated from current group bodyweight rather than from a fixed tonnage assumption. The medicated feed must not be stored beyond the marketing authorization stability window once the API premix has been diluted into a non-approved carrier blend.

Drinking-water delivery of tylvalosin tartrate begins with a water-soluble granule or powder that must disperse in potable water before the stock solution reaches the dosing proportioner. The tartrate salt dissolves most readily in water buffered to pH 6.0–7.5. Field water with a calcium carbonate equivalent above 300 mg/L slows wetting and can yield a faint haze after 30 min of stirring. If a 0.45 µm membrane filter retains visible residue, the stock solution is rejected and the source water is softened or acidified with citric acid to pH 6.5 before recompounding. Stock solutions are commonly prepared at 1:100 or 1:200 w/v, but the final drinking-water concentration depends on the proportioner setting, which may range from 0.5% to 5% by volume. A diaphragm or piston proportioner must be calibrated with the actual stock solution rather than water because viscosity and air entrapment alter the delivered volume. Potable water pH is measured per ISO 10523 and calcium/magnesium hardness per ISO 6059 before each campaign. The calibration activity is recorded in the batch log because pump drift of more than 5% can shift the delivered dose outside the approved range.

The granulation route for water-dispersible product uses a fluid-bed top-spray granulator rather than a high-shear mixer. The API premix is blended with lactose monohydrate, sodium citrate buffer, and povidone K30. The aqueous binder is sprayed at a nozzle air pressure of 1.5–2.5 bar while inlet air is held at 50–60°C. Product temperature is not permitted to exceed 40°C because macrolide degradation rises sharply when the wet cake is overheated. The dried granule is milled through a 1.0 mm screen and filled into aluminum foil sachets at water activity below 0.6. In the field, one sachet is dissolved in 10 L potable water under moderate agitation, and the resulting solution is added to a header tank. Drinking-water medication is preferred for swine that have reduced feed intake but continue to drink. The final dose is therefore controlled by water consumption monitoring rather than by fixed inclusion in feed. When a group of sick pigs reduces water intake by more than 20% relative to baseline, the operator must check the proportioner and water line pressure before adjusting the stock solution concentration.

What changes when the same active moves into poultry water medication programs?

The poultry application shifts the bioperformance target from enteric pathogens to respiratory mycoplasma control, particularly Mycoplasma gallisepticum and Mycoplasma synoviae. Broilers and turkeys regulate water intake with ambient temperature, so the medicated stock solution is usually administered through a proportional medicator that injects a set volume per 1 L of drinking water. When ambient temperature exceeds 28°C, water consumption can rise by more than 15%, which dilutes the effective concentration unless the stock solution is adjusted. Poultry lines often have a central header tank; the solution is prepared at a concentration that delivers the approved daily amount over a 3–5 day medication window. The water line flow rate is recorded every 2 h during the first day of treatment to verify that actual intake matches the predicted medication rate. Nipple drinker systems with poor line pressure cause uneven delivery to the end birds. A booster pump and pressure regulator are therefore part of the processing setup. Water bypass lines must be closed during the medication period so that untreated water does not dilute the medicated solution before it reaches the drinkers.

Formulation for poultry water medication uses a water-soluble granule with citric acid buffer to maintain solution pH below 7.0 after dilution. The finished sachet should exclude cationic surfactants because quaternary ammonium residues in water lines can interact with the macrolide and reduce antimicrobial activity. Regulatory compliance is controlled by Commission Regulation (EU) No 37/2010 for maximum residue limits and by national withdrawal requirements. The formulator must verify the withdrawal period for each target species and production class. After the medication period, distribution lines are flushed with potable water for at least 15 min to remove residual tylvalosin and prevent biofilm-driven degradation in pipes. The end product is a water-dispersible granule for direct addition to header tanks or proportioner stock bottles. It is not intended for dry feed application because the dose precision in feed is inferior to water titration in poultry houses with variable feed intake. The sachet product is manufactured in a granulation suite validated under EU GMP Annex 15, and the finished granule is tested for dissolution behaviour before release.

Tablet and capsule presentations containing tylvalosin tartrate are not the primary commercial presentations for swine and poultry, but they are formulated when individual animal dosing is required or when food-animal premix lines are undesirable. The API premix is dried, milled through a 0.25 mm screen, and blended with microcrystalline cellulose, croscarmellose sodium, and colloidal silicon dioxide before direct compression. Tablet hardness is controlled between 5 kp and 8 kp for a 500 mg tablet, but this range is not universal. It is derived from the need to balance friability below 1% against acceptable disintegration. Disintegration is run per USP <701> in water at 37 ± 0.5°C; a limit of less than 15 min is used for immediate-release veterinary tablets. Dissolution is run per USP <711> Apparatus II at 50 rpm in 0.1 M hydrochloric acid. A typical immediate-release specification is not less than 80% in 30 min, but published data for this specific tylvalosin tartrate tablet configuration is limited. The blend should be protected from excess magnesium stearate; levels above 1.5% w/w create a hydrophobic film that delays wetting and can slow dissolution beyond the acceptance window.

Capsule filling uses a dosator or tamping-pin machine with size 3 or size 4 hard gelatin capsules. The fill weight is calculated from the API premix assay and the intended dose per capsule. A target fill weight between 150 mg and 250 mg is common for pilot formulations, but the exact weight depends on the strength of the sourced premix and the required dose per animal. Powder flow is improved with 0.5% w/w colloidal silicon dioxide, and moisture is controlled by storing the filled capsules in PVC/aluminum blisters with a desiccant pocket. Weight variation is tested per USP <905>, and content uniformity is assessed on 10 units per batch. For coated tablets, a hydroxypropyl methylcellulose film at 2–3% weight gain masks the bitter taste and provides a moisture barrier. The final tablet or capsule is intended for oral administration to individual animals. It must be stored below 25°C in a dry place, and the batch record must document the API premix source, blend time, compression force, and ejection force. The operational boundary is that tablet and capsule manufacturing must be performed in a dedicated suite to avoid contamination of feed-grade product with tablet excipients.

When injection becomes the target presentation: pH and sterility constraints

Parenteral use of tylvalosin tartrate is constrained by the pH-dependent behaviour of the tartrate salt and by the absence of a widely harmonized pharmacopoeial monograph for the finished injection. Aqueous solutions are compounded in Water for Injection and adjusted to pH 5.0–7.0. Below pH 5.0 acid-catalysed hydrolysis of the saccharide linkage accelerates, while above pH 7.0 the free base can precipitate as a haze. The solution is isotonised with sodium chloride to 280–320 mOsm/kg and checked by freezing-point depression per USP <785>. Sterile filtration through a 0.22 µm polyethersulfone membrane is preferred over terminal steam sterilisation because autoclaving at 121°C for 15 min may increase total related substances beyond the specification limit. The filtered solution is filled into amber glass vials under nitrogen headspace, and filter integrity is tested before and after filling. The injection volume for swine is kept as low as possible to reduce injection-site irritation. Published data for this specific tylvalosin tartrate injection configuration is limited, so the formulator must generate tissue tolerance and depletion data before commercial release.

The manufacturing suite for an injectable solution must operate under aseptic conditions in an EU GMP Annex 15 validated line. Cleanroom classification per ISO 14644-1 class 7 or stricter is used for the background, and class 5 is used for the filling zone. Sterility is verified per USP <71>, and bacterial endotoxin is controlled per USP <85> with a limit appropriate for the intended route and bodyweight. The container closure system is selected to prevent light-induced degradation; amber glass with bromobutyl rubber stoppers is used. The final injection is not a primary commercial route for tylvalosin tartrate, but it is technically feasible when rapid onset and precise dosing are required. The formulator must confirm tissue tolerance and muscle residue depletion in the target species. Any off-label compounding must be conducted under the relevant veterinary prescription rules. The final product must not be mixed with cationic injectable excipients such as benzalkonium chloride because the quaternary ammonium group can complex with the macrolide and reduce activity.

Granulation route selection for oral powders, stock solutions, and feed premix intermediates

Dry blending and wet granulation represent two distinct downstream routes for the 625 mg/g fortified premix. Dry blending is used when the final article is a feed premix or a simple oral powder. The API premix is layered between portions of excipient inside a tumble blender or horizontal ribbon mixer. This layered loading prevents localised dust generation and reduces assay variation early in the blend cycle. Wet granulation is required when the final product must dissolve rapidly in drinking water or when dust containment is critical. A high-shear mixer or fluid-bed granulator is charged with the API premix and soluble filler. An aqueous povidone K30 binder at 5% w/w is added under controlled spray. The wet mass is milled through a 1.0 mm screen, dried at 45°C until loss on drying is below 3.0% per USP <731>, and sized to a particle distribution between 100 µm and 800 µm. Drying equipment must be validated to prevent cross-batch carryover. EU GMP Annex 15 requires three consecutive successful batches for process validation.

Table 1 summarizes critical process parameters and test methods for the main downstream routes.

The selection between these routes is governed by the final dosing accuracy required and the thermal sensitivity of the macrolide. A feed premix tolerates a wider process window because the final feed is consumed rapidly, whereas a water-soluble granule requires tight control of residual moisture and particle porosity. Oral powders for direct drenching or capsule filling are intermediate in complexity; they require particle size reduction but not dissolution rate control. All routes share the same incompatibility boundary. Prolonged contact with acidic aqueous solutions below pH 5.0 should be avoided. Cationic surfactants and high cation-exchange carriers should also be excluded from the formulation. The appropriate downstream route is therefore not determined by the active content alone. It is determined by the target species, dosing equipment, and approval status in the destination market.